Reuters logo
2 years ago
BRIEF-Galapagos advances triple combination therapy in cystic fibrosis
October 15, 2015 / 5:53 AM / 2 years ago

BRIEF-Galapagos advances triple combination therapy in cystic fibrosis

Oct 15 (Reuters) - Galapagos NV :

* Says GLPG2665 has been selected as first next generation corrector compound candidate

* GLPG2665 enters pre-clinical development and completes first Galapagos-Abbvie triple combination therapy

* Triple combination therapy of C2 with GLPG2222 and GLPG1837 expected to address 80 percent of mutations in CF population

* Expects to enter Phase 2 studies with potentiator GLPG1837 in Class III mutation patients and a Phase 1 study with corrector GLPG2222 in healthy volunteers by filing before year-end Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below